Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk

Subha Subramanian1, Chunyu Liu1, Abraham Aviv1

  • 1From the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).

Insights

Plasma stromal cell-derived factor 1α (SDF-1) levels are linked to increased risk of heart failure and all-cause mortality in individuals without traditional cardiovascular disease risk factors. Further research is needed to explore the clinical utility of SDF-1 measurements.

Area of Science:

  • Cardiovascular Science
  • Molecular Biology
  • Genetics

Background:

  • Stromal cell-derived factor 1α (SDF-1), encoded by CXCL12, interacts with the CXCR4 receptor.
  • Genetic variations in CXCL12 and CXCR4 are associated with coronary artery disease (CAD) and leukocyte telomere length.
  • Previous studies suggest links between these factors and cardiovascular health.

Purpose of the Study:

  • To investigate the association between plasma SDF-1 levels and cardiovascular disease (CVD)-related outcomes.
  • To examine the relationship of SDF-1 with CVD risk factors, leukocyte telomere length, and endothelial progenitor cells.
  • To determine the predictive value of SDF-1 for heart failure, myocardial infarction, and mortality.

Main Methods:

  • Plasma SDF-1 levels were measured in 3359 participants of the Framingham Heart Study.
  • Cox regression analysis was used to assess associations with incident CVD, myocardial infarction, heart failure, and all-cause mortality.
  • Linear regression evaluated relationships with risk factors, leukocyte telomere length, and CD34+ cell phenotypes.

Main Results:

  • Higher SDF-1 levels correlated with older age, lower high-density lipoprotein-cholesterol, and less smoking.
  • SDF-1 levels were associated with lower CD34+ cell frequency but not leukocyte telomere length.
  • After adjusting for risk factors, elevated SDF-1 was linked to increased risk of heart failure and all-cause mortality, but not overall CVD or myocardial infarction.

Conclusions:

  • Plasma SDF-1 levels are independently associated with an increased risk of heart failure and all-cause mortality.
  • The association with myocardial infarction was diminished after accounting for high-density lipoprotein-cholesterol.
  • Further studies are warranted to ascertain the clinical utility of SDF-1 measurements in CVD risk assessment.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.7K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
750
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.5K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.4K